Impact of N-803 on peripheral blood cell subsets. Cryopreserved PBMCs were assessed by flow cytometry immediately before (day 0) and at the indicated timepoints after initiation of N-803 treatment. (A) The absolute numbers of cells per microliter of peripheral blood for each subset was determined by multiplying the percentage of a given cell type (relative to the total CD45⁺ population) by the overall white blood cell count. Fold changes in each subset are relative to the baseline (day 0) sample. (B) Relative percentages of naive, central memory (CM), effector memory (EM), and CD45RA-expressing effector memory (EMRA) CD3⁺CD4⁺ or CD3⁺CD8⁺ T cell subsets. (C) Relative percentages of CD3⁺CD4⁺ or CD3⁺CD8⁺ T-cell subsets expressing the chemokine receptors CD183 (CXCR3), CD194 (CCR4), and/or CD196 (CCR6). The Th1, Th2, and Th17 designated in parentheses are only applicable to the CD3⁺CD4⁺ T cell subset. (D) The percentage of CD3⁺CD4⁺ or CD3⁺CD8⁺ T cells expressing cell-surface antigens that are altered during T cell activation. (E) The percentage of CD3⁺CD4⁺ or CD3⁺CD8⁺ T cells expressing molecules involved in immune checkpoint regulation. (F) The percentage of CD3⁺CD4⁺ or CD3⁺CD8⁺ T cells expressing intracellular perforin (Pfn), granzyme B (GzmB) or the proliferation marker KI67.